Zota Healthcare Secures Key Cambodian Licenses, Expands Antibiotic Footprint

Zota Healthcare Ltd. has bolstered its global presence by securing product registration licenses in Cambodia, including approval for Azitoz 500 (azithromycin 500mg tablets), valid for five years. This antibiotic joins 12 other products registered in Cambodia, such as Ciprovar-500 and Zedgra 100, enhancing Zota’s export portfolio. The licenses, renewable post-2023, enable the company to tap into Southeast Asian markets, aligning with its strategy to diversify beyond domestic sales.

 

Earlier, on March 17, 2025, Zota announced licenses for Zotalan 30 (acid reflux treatment) and RTFIT (liver ailment drug), signaling aggressive expansion in therapeutic segments. The company, a WHO-GMP certified exporter, already supplies to Sri Lanka, Vietnam, Canada, and others.

 

Source: Zota Healthcare filings, Marketscreener (2025)